2) which initiates fatty acid synthesis. Various genetic disorders have been described in which there is a deficiency of one or more of these enzyme activities.
Deficiency of PCC activity results in propionicacidemia, a disorder in which extensive clinical heterogeneity has been observed (1, 2) . In its most debilitating form, it is one of the causes of the ketotic hyperglycinemia syndrome (1), a condition that is usually lethal in the neonatal period. Other individuals may be less severely affected (3) (4) (5) and one case has been reported in which expression of the enzymq deficiency was virtually benign (6) .
To examine the extent and basis ofthe genetic heterogeneity observed in patients with a PCC defect, we undertook a study of complementation between fibroblasts strains from such patients (7) . Two major complementation groups, pccA and pccBC, were revealed among seven mutant strains. These groups may cor-respond to separate genes involved in the expression of PCC, or they may have resulted from intragenic events. Some patients have been described with an organic aciduria in whom correction of the biochemical abnormality has been attempted with biotin therapy (8) (9) (10) (11) . One such biotin-responsive patients, originally described by Gompertz and his colleagues (8) , presented with 8-methylcrotonylglycinuria and was shown to have a combined deficiency of two carboxylase activities, PCC and MCC (12, 13) . Weyler et al. (13) reported that both enzymes had normal activity in fibroblasts cultured in biotin-supplemented medium (24 .gIliter) but little or no activity when the biotin content was reduced by a factor of 10 . The authors postulated a defect of the holocarboxylase synthetase, the enzyme required to bind the biotin cofactor to apocarboxylase. Recently, Roth et al. reported a patient who presented with f3-methylcrotonic aciduria associated with lacticacidosis (10) . This patient also responded clinically to biotin administration, but succumbed to complications of cyanotic congenital heart disease.
In this study, we have characterized additional mutant strains to confirm the nature of the complementation map and to determine if a new complementation group, defined by the biotin-responsive disorder described above, exists. In addition, we have demonstrated a deficiency of yet another enzyme activity, that of pyruvate carboxylase, in fibroblasts of biotinresponsive patients grown under biotin-free conditions.
METHODS
Source and growth of cells. All strains were subcultures of skin fibroblasts derived from patients with propionicacidemia or biotin-responsive organicaciduria. The clinical histories of the biotin-responsive patients have been reported (8, 10) . Strains previously mapped to complementation groups have been described (7) . Several of the strains were kindly provided by Dr Cells were collected in 15-20 ml of the appropriate medium and centrifuged at 800 g for 10 min. The pellets were washed once with 15 ml and once with 1 ml cold phosphate-buffered saline and centrifuged at 2,000 rpm for 10 min after each washing. The pellets were resuspended in 50 ,ul of 1 mM dithiothreitol/106-107 cells. The cell suspensions were sonicated on ice with a 10-s burst at setting 20 on an Artek biodismembrator (Fisher Scientific Co., Pittsburgh, Pa.).
Propionyl-CoA carboxylase, ,3-methylcrotonyl-CoA carboxylase, and pyruvate carboxylase were assayed by determining the enzyme-dependent incorporation of ['4C]bicarbonate into acid-nonvolatile form. All three enzyme assays were linear for 0-20 min and from 0-70,g protein per assay tube. The PCC assay was modified from our previous procedure (7) by the addition of 0.1% Triton X-100 (Rohm and Haas Co., Philadelphia, Pa.) ( Table I ). The assay volume was reduced to 0.05 ml.
The MCC assay (Table I) was modified from the method of Weyler et al. (13) . The assay mix contained in a vol of 0.05 ml: 60 mM Tris-HCl pH 8.2, 10 mM reduced glutathione, 10 mM MgCl2, 2 mM neutralized ATP, 0.1% Triton X-100, 50 mM KCI, 0.5 mM EDTA, 3 mM ,-methylcrotonyl-CoA (P-L Biochemicals, Inc., Milwaukee, Wis.) and 10 mM ['4C]NaHCO3 (12. 2mCi/mmol; New England Nuclear, Boston, Mass.). Blank tubes were prepared by omitting the 13-methylcrotonyl-CoA.
The PC assay (Table I) 
RESULTS
Complementation analysis. 14 new biotin-nonresponsive mutant strains with PCC deficiency were examined for complementation with "tester" strains from the established complementation groups (7) . The results ofthese tests are shown in the complementation map in Fig. 1 (normal) after growth in biotin-supplemented or biotinfree medium (Fig. 2) . Normal cells from both biotinfree ( Fig. 2a) and biotin-supplemented (Fig. 2d ) cultures were completely covered with silver grains, showing that PCC activity was not appreciably affected by biotin starvation. Neither the pccA mutant, strain 447 ( Fig. 2b and e) , nor the pccBC mutant, strain 500, was able to incorporate the label after growth in either medium. These mutants are unable to metabolize propionate because of their genetic defect, and they are not sensitive to exogenous biotin concentration. The biotin-responsive strains 456 (Fig. 2f) 2c, strain 456) after growth in biotin-free medium for 2 wk before transfer to the isotope medium.
The above results showed that complementation could be examined in biotin-responsive strains. They were fused with each other and with tester strains from each of the previously defined pcc complementation groups after growth in biotin-free medium. Negative controls were generated by self-fusion. Fig. 3 shows the silver grain patterns obtained for fusions involving strain 456. Fusions with either a pccA (Fig.  3a) or a pccBC (Fig. 3b) (18, 19) .
The specific activities of PCC, MCC, and PC were examined in fibroblast extracts of mutant and normal strains after prolonged cultured in biotin-supplemented and biotin-free media. As shown in Table III t ND, not determined. 500 (pccBC) were also examined after growth in biotinfree or biotin-supplemented medium (Table III) . All four strains showed <5% of control PCC activity after growth in either medium, whereas MCC and PC activities were normal. These pcc mutants are therefore only deficient in PCC activity and the defect is unresponsive to biotin supplementation. In contrast, the bio mutant strains 456 and 541 displayed a multiple carboxylase defect that depended on biotin depletion for its expression. The PCC and MCC activities of the bio strains were within the low normal range under routine culture conditions in biotin-supplemented medium (Table III) . Interestingly, the PC activities were well above the normal range established for strain 595 and the various pcc strains. Transfer of bio cells to biotin-free medium produced a dramatic decrease in the activities of all three enzymes from normal to background levels. 
DISCUSSION
To investigate the genetic basis of clinical heterogeneity in propionicacidemia, we previously examined complementation between PCC-deficient mutant fibroblast strains. Our results revealed two major complementation groups, designated pccA and pccBC and confirmed the recessive expression of PCC deficiency in heterokaryons (7) . Clinical heterogeneity was not correlated with genetic heterogeneity, since two patients, one with a lethal disorder and the other with a very mild expression, were assigned to the same complementation group (pccC). With the addition of the new mutants in this study, our results have been extended considerably, with the following conclusions. We have confirmed that pccBC is a complex group consisting of two subgroups, pccB and pccC. Mutant strains in pccB complement strains in pccC, but fail to correct the defect in pccBC strains. This is a pattern that would be expected for intragenic complementation within a pccBC gene. If so, it is surprising that there would be so many such mutants, since intragenic complementation would be expected to occur as a rare event. The number ofpccBC mutants would have been expected to predominate. It implies that the mutant gene product, possibly a polypeptide of PCC or holocarboxylase synthetase, has two centers of function such that a defect in one does not inactivate the other. Such an explanation for intrageinic complementation has been presented before, notably for 8-galactosidase of Escherichia coli (20) .
If all the pcc coinplementation groups represented the same gene, then a class of mutants called pccABC should have been found. In fact, this would have been expected to be the predominant class, since all of the other complementation groups would have resulted from the "rare" case of intragenic complementation. Thus, with the mapping of some 23 pcc inutants, the absence of the pccABC class strongly suggests that pccA and pccBC represent two separate genes, perhaps encoding different subunits of PCC (21) (22) (23) .
We have shown that three carboxylases, PCC, MCC, and PC, were deficient in fibroblast extracts of two patients who responded clinically to biotin administration. Fibroblasts of these two patients failed to complement each other in heterokaryons, but did complement members of every other pcc group. This establishes a new complementation group, bio, in PCC deficiency. The complementation results also show that the bio mutation must be expressed recessively, since a dominant mutation would have failed to complement the known pcc groups. Although our studies show that these patients have allelic mutations, they showed differences clinically. J.R. (strain 456) was studied at 5 mo of age with metabolic acidosis and ketosis and a severe erythematous rash (8) . B.B. (strain 541) presented, immediately after birth, the metabolic acidosis, ketosis, and lactic acidemia progressing to seizures and death in 5 d (10) .
Both patients had an organicaciduria, which could have predicted all three carboxylase defects. They both excreted abnormal amounts of /-methylcrotonate and ,8-hydroxyisovalerate and J.R. also excreted f3-methylcrotonylglycine (10, 24, 25) . These findings are consistent with the deficiency of MCC activity. In addition both patients excreted f8-hydroxypropionate and J.R. also excreted propionate, methylcitrate, and tiglylglycine, findings consistent with the PCC defect. Finally, both patients excreted large amounts of lactate and a lacticacidosis was also demonstrated in BB. These findings correlate with a deficiency of PC activity. These results emphasize the importance of screening urinary organic acids in the differential diagnosis of this multiple carboxylase disorder during the neonatal period.
The bio mutants can be distinguished biochemically from normal cells and members of the other PCCdeficient complementation groups by the dramatic change in their carboxylase activities on transfer to biotin-free conditions. Even after 8 wk culture in biotin-free medium, normal fibroblasts retained at least 90% of their initial carboxylase activities (Table III) . In contrast, under the latter conditions, strain 456 showed no detectable carboxylase activities. Strain 541, which does not complement strain 456, exhibited similar carboxylase deficiencies. All three enzyme activities returned to normal levels when the cells of both strains were subcultured into biotin supplemented medium. These results reflect the biotin responsiveness of at least one of the patients. All of the symptoms ofJ.R. resolved rapidly upon the oral administration of 10 mg biotin/d, and he remains clinically well while receiving 0.5 mg/d (26) . In B.B. there was some improvement of the metabolic acidosis on intravenous administration of 0.2 mg of biotin, but death occurred the following day (10) .
A pleiotropic deficiency ofthree carboxylases such as that found in the bio mutants could be accounted for by a defect either in biotin transport at the cellular or mitochondrial level, or in the holocarboxylase synthetase. It 
